NEW YORK, June 28 - Entigen has hired Denise Gilbert, a former executive at Incyte and Affymax, as the company's new CEO, Entigen announced Thursday.
As CEO, Gilbert will work on marketing Entigen's technology platform and expanding the business beyond its traditional focus on bioinformatics. The company has yet to disclose specifics on its new direction.
Gilbert joins Entigen after serving as executive vice president and chief financial officer at Incyte. Prior to that, she served as vice president and chief financial officer at Affymax, (the company that spawned Affymetrix) where she participated in the company's 1995 acquisition by Glaxo Wellcome.
Prior to her six years as an executive in genomics companies, Gilbert, a PhD-trained biologist, spent seven years as a biotechnology analyst on Wall Street.
"Denise understands the technical challenges researchers must overcome to make productive use of abundant but geographically dispersed, heterogeneous life science data, can articulate the role of Entigen as a commercial solutions provider, and has the internal and external corporate management experience needed to execute our corporate strategy," Entigen chairman Bala Manian said in a statement.
Entigen, based in Sunnyvale, Calif., was formed in December 2000 from the merger of eBioinformatics, a provider of online software tools for life science data analysis, and Empatheon, which developed ADAAPT (Advanced Dynamic Access, Analysis, and Personalization Technology), a Java-based technology for accessing multiple types of biological data.